Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
Project Summary
Extensive studies have been conducted to define the development, conversion, stability, and regulatory
mechanisms of CD4+Foxp3+ regulatory T cells (Tregs) in homeostasis and a variety of disease models. It is
well-known that Tregs are recruited, converted, and expanded in the tumor microenvironment and act as one
of the major immunosuppressive mechanisms dampening spontaneous tumor-associated antigen (TAA)-
specific T cell immunity and immunotherapy and active vaccination induced anti-tumor immunity. However, how
Tregs behave in the metabolically abnormal tumor microenvironment remains unknown.
The Warburg effect is an important metabolic feature in many types of cancer. Given that nutrients including
glucose are poorly replenished in the tumor, it is assumed that T cell glycolytic metabolism has been altered
due to the Warburg effect in the tumor microenvironment. In support of this, poor glycolysis can alter effector
memory T cell function in the tumor microenvironment. In addition, the oxygen-sensing prolyl-hydroxylase
proteins, necrotic cells released potassium ions, and abnormal zinc metabolism can impair effector T cell
function in the tumor microenvironment. These studies underscore the significance of metabolic regulation of
memory T cells in the tumor.
Tregs exhibit a memory and effector phenotype in the human tumor microenvironment. It is unknown whether
Tregs are subject to glycolytic regulation in the tumor. Furthermore, oxidative stress is an additional metabolic
feature in the tumor microenvironment. Myeloid dendritic cells (DCs) are phenotypically and functionally altered
by oxidative stress in the tumor microenvironment. However, it is unknown whether oxidative stress alters Treg
phenotype and function in the tumor and affects cancer immunotherapy. To address these questions, we have
examined the phenotypic and functional nature of Tregs in human ovarian cancer and several types of mouse
cancer. We have found that Tregs are highly apoptotic in the tumor microenvironment. Interestingly, apoptotic
Tregs are superior suppressors via a distinct mechanism. Furthermore, oxidative stress, rather than glycolysis,
is a metabolic mechanism controlling tumor Treg functional behavior and tempering therapeutic efficacy of
immune checkpoint therapy. This project is to conduct comprehensive molecular, functional, translational, and
clinical research on the nature of Tregs and their metabolic pathway in the cancer microenvironment. We will
provide rich opportunities to take our understanding of Treg biology in the tumor to a new level of basic and
practical application. Our specific aims are:
Aim 1 is to test our hypothesis that oxidative stress controls Treg apoptosis in the tumor
microenvironment. Aim 2 is to determine the molecular mechanisms controlling the energy circuit
of Tregs and the interaction between Tregs and APCs in tumor.
Public Health Relevance Statement
Project Narrative
It is poorly understood how Tregs are affected by tumor metabolism in the tumor microenvironment. We will
explore the molecular mechanisms of Treg apoptosis, energy circuits, and the metabolism-associated
suppressive mode of action of Tregs. The proposal will provide an opportunity to take our understanding of
Treg biology in the tumor to a new level of mechanism and application.
No Sub Projects information available for 1R01CA244827-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01CA244827-01A1
Patents
No Patents information available for 1R01CA244827-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01CA244827-01A1
Clinical Studies
No Clinical Studies information available for 1R01CA244827-01A1
News and More
Related News Releases
No news release information available for 1R01CA244827-01A1
History
No Historical information available for 1R01CA244827-01A1
Similar Projects
No Similar Projects information available for 1R01CA244827-01A1